The recent phase 3 RUBY trial showed that the addition of dostarlimab-gxly to chemotherapy provided a survival benefit in patients with primary advanced or recurrent endometrial cancer (EC), especially in those with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) and TP53 mutations. The dostarlimab combination significantly improved progression-free survival and overall survival rates in the dMMR/MSI-H and TP53-mutated subgroups compared with placebo plus chemotherapy. The trial’s results suggest that dostarlimab and carboplatin/paclitaxel could be a new standard of care for newly diagnosed patients with these specific molecular profiles of EC.
Reference: Berberabe T. Subgroup Analysis Shows Dostarlimab/Chemotherapy Elicits PFS Benefit in dMMR/MSI-H, TP53+, and NSMP Endometrial Cancer. Published October 23, 2023. Accessed November 6, 2023. https://www.onclive.com/view/subgroup-analysis-shows-dostarlimab-chemotherapy-elicits-pfs-benefit-in-dmmr-msi-h-tp53-and-nsmp-endometrial-cancer
